^
    Back
    Association details:
    Biomarker:EGFR mutation + ALK negative + TMB-H
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

    Published date:
    12/28/2018
    Excerpt:
    Recommendation 5: first-line treatment of NSCLC without a druggable oncogene driver: Nivolumab plus ipilimumab represents a treatment option regimen for patients with PS 0–1, EGFR and ALK negative NSCLC with a high TMB, regardless of tumour PD-L1 expression level, if approved and available [A=83%, B=17% and I, A].
    DOI:
    10.1093/annonc/mdy554